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Abstract: The twentieth century ended with human African trypanosomiasis (HAT) epidemics
raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs
aiming to contain the disease had ground to a halt, given previous success against HAT and
the competing priorities associated with other medical crises ravaging the continent. A series of
dedicated interventions and the introduction of innovative routes to develop drugs, involving Product
Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by
Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of
existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1
HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical
trials for this compound demonstrated the possibility of conducting such trials in the resource-poor
settings of rural Africa. The Drugs for Neglected Disease initiative (DNDi), founded in 2003, has
developed the first all oral therapy for both stage 1 and stage 2 HAT in fexinidazole. DNDi has also
brought forward another oral therapy, acoziborole, potentially capable of curing both stage 1 and
stage 2 disease in a single dosing. In this review article, we describe the remarkable successes in
combating HAT through the twenty first century, bringing the prospect of the elimination of this
disease into sight.
Keywords: human African trypanosomiasis; sleeping sickness; elimination; chemotherapy;
fexinidazole; pafuramidine; acoziborole
1. Introduction
The current drugs used for human African trypanosomiasis (HAT) (Figure 1) have served their
purpose for many years. The incidence of HAT is now at a historic low (fewer than 1000 cases
reported in 2018 [1]). Two forms of the disease occur. The one found in West and Central Africa is
caused by Trypanosoma brucei gambiense, and the other, found in East and Southern Africa, is caused by
Trypanosoma brucei rhodesiense. The former causes a chronic disease, taking years between infection
and death, while the latter may kill within weeks to months. Parasites injected into the bloodstream
cause a stage 1 infection, where replication is primarily associated with blood and lymph. However,
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the parasites then invade other organs, including the central nervous system (CNS). Once replicating
in the CNS, the disease progresses to stage 2, where many of the symptoms of sleeping sickness
become manifest. The current drugs suffer many drawbacks [2]. For stage 1 disease, either suramin or
pentamidine is used for HAT caused by T. b. rhodesiense and T. b. gambiense, respectively. Both drugs
must be given by injection for a prolonged period, and both carry a risk of adverse events. For stage 2
disease, the highly toxic melarsoprol is still the treatment of choice for rhodesiense HAT. Melarsoprol
causes an encephalopathic syndrome that is fatal in up to one in twenty people taking the drug [3].
For gambiense HAT, the past decade has seen the introduction of a combination therapy. Intravenous
eflornithine is given for 10 days alongside oral nifurtimox for 14 days [4].Trop. Med. Infect. Dis. 2020, 5, x FOR PEER REVIEW 3 of 15 
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Figure 1. Different drugs have been used to treat HAT depending on the trypanosome subspecies 
causing the disease, and whether progression is at stage 1 or 2. For the past decade nifurtimox and 
eflornithine combination therapy has been the treatment of choice for stage 2 T. b. gambiense disease, 
and pentamidine for stage 1. For rhodesiense HAT, stage 2 is treated with melarsoprol and stage 1 
with suramin. 
2. Pafuramidine—A New Paradigm in Anti-Trypanosomal Drug Development 
Among the currently used drugs for HAT is pentamidine, a diamidine that was introduced in 
the 1940s, and has been the mainstay in the treatment of stage 1 gambiense HAT for nearly 80 years 
[26]. Another diamidine, diminazene, is used in treating veterinary trypanosomiasis [27]. The 
diamidines are di-cations, with positive charges at either end, which renders them highly polar, 
precluding bioavailability if taken orally [28]. Pentamidine is typically given by intramuscular 
injection for seven days. Das and Boykin showed in the 1970s that methoxy-derivatives of other 
diamidines acted as orally available prodrugs, and the methoxy group metabolized back to the 
amidine systemically [29].  
The Bill and Melinda Gates Foundation was founded in 2000, a time when the resurgence of 
HAT was at its pinnacle. Among the Foundation’s earliest supported projects was the development 
of the diamidine methoxy-prodrug approach towards new drugs for HAT through the CPDD. 
DB289 (Figure 2) (pafuramidine maleate; 2,5-bis(4-amidinophenyl)-furan-bis-O-
methylamidoxime), the methoxy product of furamidine (2,5-bis(4-amidinophenyl)-furan), in which 
the benzamidine moieties are separated by a furan ring, emerged as the lead compound for 
progression. 
Furamidine is highly polar and unable to traverse lipid bilayers without the assistance of 
transporters (see later). Pafuramidine, however, has much greater capacity to diffuse across 
membranes [30], including the intestinal epithelium, giving it considerable oral bioavailability. Once 
systemic, it is metabolized via various cytochrome P450 enzymes and cytochrome b5 reductase [31–
36] to furamidine. Preclinical safety and efficacy results [37,38] were sufficient to enable the passage 
to clinical trials. 
 
Figure 1. Different drugs have been used to treat HAT depending on the trypanosome subspecies
causing the disease, and whether progression is at stage 1 or 2. For the past decade nifurtimox and
eflornithine combination therapy has been the treatment of choice for stage 2 T. b. gambiense disease,
and pentamidine for stage 1. For rhodesiense HAT, stage 2 is treated with melarsoprol and stage 1
with suramin.
The combination is relatively safe and efficacious. However, the delivery of kilogram quantities
of eflornithine and many liters of sterile saline brings substantial logistical difficulty. For melarsoprol,
resistance was a growing problem in the early 2000s [5], and for eflornithine [6] and nifurtimox [7]
independently, resistance can be readily selected in the laboratory. There is no doubt that better drugs
for use against HAT are required [8].
The first two decades of the twenty first century can be seen as a major success story in regards
to intervention against this neglected tropical disease. HAT was running out of control in the late
twentieth century, with an estimated 300,000 people infected [9]. In response, the international
com unity launched several key initiatives, which can be seen as having converged to turn the tide.
Consequently, the twenty first century has witnessed a dramatic change in the trajectory of HAT.
In 1999, Médecins Sans Frontières (MSF) initiated their “Access” campaign to encourage a
re-engagement of the pharmaceutical industry with neglected diseases, including HAT [10]. A key
study [11] revisited the administration regimen of melarsoprol based on pharmacokinetic data.
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An effective 10-day administration protocol, which diminished hospitalization time for patients [12],
albeit without increasing safety, was introduced to great effect [13]. This IMPAMEL program (“improved
application of melarsoprol”) was crucial in implementing the first modern clinical trials on HAT,
and also in demonstrating the feasibility of conducting trials in extremely resource-limited conditions
according to Good Clinical Practice, laying the foundation for future developments.
Eflornithine had been shown to be far safer than melarsoprol as treatment for stage 2 disease [14].
Yet, by the late 1990s, no pharmaceutical company was prepared to make this compound for HAT
treatment. However, when it was discovered that the same compound could prevent the growth
of unwanted facial hair in women, a number of drug companies saw an opportunity to market the
compound for this purpose [15]. MSF, already campaigning for access to essential medicines, were
able to make a compelling case that society needed to rethink drug discovery paradigms for neglected
diseases [16]. Aventis (now Sanofi) were persuaded to develop the drug and donate it at no cost to the
World Health Organization (WHO) for distribution in Africa. Millions of dollars were also provided by
Aventis/Sanofi to WHO, who could now develop new screening and intervention programs. The Bill
and Melinda Gates Foundation selected HAT to be one of the first diseases they targeted through
the Consortium of Parasitic Drug Development (CPDD) [17], and the Drugs for Neglected Diseases
initiative (DNDi) was founded through MSF [18] to seek new drugs for diseases including HAT.
In diagnostics, the Foundation for Innovative New Diagnostics (FIND) sought novel ways of improving
our ability to detect HAT patients [19], and new ways of combating the tsetse fly were rolled out too [20].
A number of pharmaceutical companies also regained an interest in HAT, including GlaxoSmithKline
(GSK) through their Tres Cantos Open Lab foundation [21] and the Novartis Institute for Tropical
Diseases (NITD) [22]. Small companies too, such as Immtech Pharmaceuticals Inc., Scynexis and
Anacor Pharmaceuticals Inc. in the USA, also raised investment to develop new drugs against HAT.
The first twenty years of the twenty first century have now seen the clinical trials and ultimate failure
of a new orally available diamidine prodrug [23], the registration of the first all-orally available therapy
against stage 2 disease [24], and the entry into clinical trials of a compound that may cure stage 2 HAT
with a single oral administration [25]. This article outlines the successes seen in the development of
new drugs for HAT in the twenty first century.
2. Pafuramidine—A New Paradigm in Anti-Trypanosomal Drug Development
Among the currently used drugs for HAT is pentamidine, a diamidine that was introduced in the
1940s, and has been the mainstay in the treatment of stage 1 gambiense HAT for nearly 80 years [26].
Another diamidine, diminazene, is used in treating veterinary trypanosomiasis [27]. The diamidines
are di-cations, with positive charges at either end, which renders them highly polar, precluding
bioavailability if taken orally [28]. Pentamidine is typically given by intramuscular injection for seven
days. Das and Boykin showed in the 1970s that methoxy-derivatives of other diamidines acted as
orally available prodrugs, and the methoxy group metabolized back to the amidine systemically [29].
The Bill and Melinda Gates Foundation was founded in 2000, a time when the resurgence of HAT
was at its pinnacle. Among the Foundation’s earliest supported projects was the development of the
diamidine methoxy-prodrug approach towards new drugs for HAT through the CPDD.
DB289 (Figure 2) (pafuramidine maleate; 2,5-bis(4-amidinophenyl)-furan-bis-O-methylamidoxime),
the methoxy product of furamidine (2,5-bis(4-amidinophenyl)-furan), in which the benzamidine
moieties are separated by a furan ring, emerged as the lead compound for progression.
Furamidine is highly polar and unable to traverse lipid bilayers without the assistance of
transporters (see later). Pafuramidine, however, has much greater capacity to diffuse across
membranes [30], including the intestinal epithelium, giving it considerable oral bioavailability.
Once systemic, it is metabolized via various cytochrome P450 enzymes and cytochrome b5
reductase [31–36] to furamidine. Preclinical safety and efficacy results [37,38] were sufficient to
enable the passage to clinical trials.
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Figure 2. Clinical trials with pafuramidine (DB289), which is the prodrug of furamidine (DB75), failed 
due to the appearance of renal toxicity during extended phase I safety profiling. The aza-derivatives 
including DB868—a prodrug of DB829, and DB844—a prodrug of DB820, also showed activity against 
stage 2 disease, but development was halted following identification of the toxicity associated with 
pafuramidine. Fexinidazole has been approved for use by the European Medicines Agency in 2018. 
The compound is converted to sulfoxide then sulfone derivatives after administration. Acoziborole is 
a benzoxaborole in clinical trials, where the efficacy of a single dosing of the drug as an oral 
medication against stage 2 disease is being assessed. 
2.1. Clinical Trials of Pafuramidine 
Ultimately pafuramidine failed in clinical trials [23,39]. However, those trials were of great 
importance, not only in testing the efficacy of this promising lead compound, but also in informing 
on any criteria required to conduct clinical trials for regulatory purposes in a cohort of patients in 
difficult places to work. These trials also helped to establish protocols for patient seeking, screening, 
drug administration, record keeping and patient follow-up post-treatment. The very fact that over 
350,000 individuals were screened in the quest for patients to include in the trials had a major impact 
on the incidence of the disease. Patients testing positive but failing inclusion criteria (i.e., not clearly 
in stage 1 disease), were treated with other drugs appropriate to their stage.   
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2.1. Clinical Trials of Pafuramidine
Ultimately pafuramidine failed in clinical trials [23,39]. However, those trials were of great
importance, not only in testing the efficacy of this promising lead compound, but also in informing on
any criteria required to conduct clinical trials for regulatory purposes in a cohort of patients in difficult
places to work. These trials also helped to establish protocols for patient seeking, screening, drug
administration, record keeping and patient follow-up post-treatment. The very fact that over 350,000
individuals were screened in the quest for patients to include in the trials had a major impact on the
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incidence of the disease. Patients testing positive but failing inclusion criteria (i.e., not clearly in stage 1
disease), were treated with other drugs appropriate to their stage.
An original phase I safety study (unpublished), carried out in healthy Caucasian volunteers in
Germany in 2001 showed the drug to be well tolerated in single and multi-dose testing (100 mg twice
per day ( b.i.d.)) and up to 600 mg in a single dose.
A phase IIa study [39] in Viana, Angola and the CDTC Maluku, Democratic Republic of the Congo
(DRC) with 32 patients showed that 100 mg of pafuramidine orally twice a day for 5 days yielded
loss of all visible trypanosomes in blood 24 h after treatment cessation in 93% of cases, compared to
100% efficacy with 7-day pentamidine treatment. However, prolonged follow up began to pick up
enhanced relapse rates from this five-day dosing (by 24 months, only 67% of pafuramidine-treated
patients were considered cured). 81 patients had entered a phase IIb trial, at the same 5-day dosing
(40 for pafuramidine and 41 for pentamidine) [39] by this time. However, the high relapse rate after
prolonged follow up in the phase IIa-1 trial prompted a decision to use a 10-day dosing of 100 mg
pafuramidine b.i.d. instead, and 30 more patients were enrolled for this phase IIa-2 trial. The dose
was well tolerated over 10 days, and was less toxic than pentamidine [39]. The 10-day dosing of
pafuramidine gave 93% cure at 3 months follow up, and was selected for a Phase III trial.
The Phase III trial [23], conducted in several centers in the Democratic Republic of the Congo,
Angola, and South Sudan recorded a cure rate of 89% at 12 months follow up. The major safety
concern noted in these treatment trials was a 7% incidence of increased liver enzymes; however,
the incidence of this adverse event was substantially less than in the comparator group treated with
pentamidine (77%). A significantly lower percentage (2% vs. 9%) of patients treated with pafuramidine
experienced treatment emergent adverse events detected by renal and urinary tract investigations
and urinalyses compared to those under pentamidine. Overall, three subjects in the pafuramidine
treatment groups were reported to have serious adverse events that could be considered acute renal
failure or insufficiency classified as possibly associated with study drugs [23].
As the phase II/III trial was progressing, a further phase I safety trial was conducted in South
Africa, necessitated by the increase in the duration of drug administration and the limited number of
patients exposed to pafuramidine (unpublished). One hundred healthy sub-Saharan African adult
volunteers were treated with 100 mg pafuramidine b.i.d. for 14 days. Generally, a mild and reversible
increase of liver enzymes was observed in multiple subjects, which had been anticipated [23]. However,
6 of 100 subjects then experienced delayed renal insufficiency with unclear etiology.
The delayed action might indicate a possible immunological role; HAT is itself immunosuppressive,
which could explain why the incidence of kidney injury in treated patients was much lower. Another
hypothesis was a genetic origin across a diverse group of individuals, which was supported by a
retrospective study on a panel of 34 genetically distinct mouse strains [40]. Urinary secretion of the
kidney injury molecule-1 (KIM-1) protein was used as a marker of proximal tubule injury in the
kidney. Only a subset of the mice revealed elevated KIM-1. Genetic association studies then showed
several genes with alleles associated with the KIM-1 levels. This included PCSK5, a serine peptidase
associated with lipid and cholesterol metabolism, and another cholesterol-associated enzyme, sterol
O-acyltransferase, among others. Definitive explanations for the kidney injury mechanism, however,
remain obscure. DNA from the subjects involved in the clinical trial was not available to determine
whether the same genes were associated to kidney damage in humans.
The appearance of unanticipated toxicity with pafuramidine led to the end of clinical development
and also a cessation of other activities around the diamidine project. This was unfortunate, since the
project had also identified several aza-analogs, including DB820 and DB829 (alongside their respective
methoxyamidine prodrugs DB844 and DB868,), which were effective in mouse [41] and vervet monkey
(Chlorocebus pygerythrus) models of stage 2 infection [42]. Significantly, DB829 accumulated far less
(>10 fold) inside mammalian cells than furamidine [43], pointing to a potentially improved safety
profile. For HAT, however, the successes that have occurred with other compounds (see below) indicate
that the diamidines are unlikely to be resurrected for future work. However, because of their diverse
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and intriguing biological activities [44], it is likely to see them re-emerging for other conditions in the
future [45].
2.2. Pafuramidine: Mode of Action and Resistance Risk
Furamidine, like other diamidines, binds to the minor groove of the DNA double helix [28,45].
The ability to bind is structure-dependent, and intriguing work has aimed to tailor this binding
to specific DNA sequences, including regulatory elements [44], with a view to controlling gene
expression in, for example, human cancer cells. Furamidine is fluorescent, and its accumulation in
trypanosomes shows binding to both the kinetoplast (mitochondrial DNA) and nuclear DNA, as well
as its accumulation in vesicles assumed to be acidocalcisomes [46]. The compound accumulates to
millimolar concentration, even in cells exposed to low micromolar concentrations over 24 hours [46].
Even a brief exposure (<5 min) to 32 micromolar of the compound, followed by wash out, provoked
death 48 hours later [47]. At 3.2 micromolar, exposure time rose to 1 hour to achieve this slow
commitment to death. Lanteri also showed a profound decrease in the mitochondrial membrane
potential associated with the addition of furamidine to T. brucei [48].
The F1Fo ATP synthase complex is an essential mitochondrial complex in trypanosomes.
In procyclic forms it acts in a classical fashion, producing ATP as part of the electron transport
chain. In bloodstream forms, however, it acts in reverse: consuming ATP in order to maintain the
essential mitochondrial membrane potential. All of the F1Fo ATPase subunits are encoded in the
nucleus, apart from subunit A6, which is encoded in the kinetoplast. Mutations to the nuclearly-encoded
gamma subunit (e.g., L262P substitution or an alanine deletion at amino acid position 281) allow the
mitochondrial membrane potential to be generated in bloodstream form trypanosomes without subunit
A6, rendering the kinetoplast redundant in this life cycle stage. The kinetoplast can be removed from
these cells without apparent impact on viability [49]. The ATPase gamma mutants (now kinetoplast
independent) are hundreds of fold resistant to phenanthridine compounds; intriguingly however, only
very minor resistance (~ 3-fold) was shown for furamidine [50]. This would indicate that, in contrast to
phenanthridines, it is not the kinetoplast per se that is the target of furamidine.
Diamidines also act against yeast mitochondria [51] with Saccharomyces cerevisiae that are fermenting
glucose, rather than respiring using mitochondrial substrates (e.g., glycerol), being 200-fold less sensitive
to pentamidine [52].
Mammalian cells too are vulnerable to diamidines. However, the hypersensitivity of trypanosomes
to this class is due to their ability to accumulate diamidines to very high concentrations across
their plasma membrane through specific transporters. The P2 aminopurine transporter, TbAT1,
which normally carries adenosine and adenine, was the first transporter characterized to carry
pentamidine [53]. Subsequently, a high affinity pentamidine transporter [54], later revealed as the
aquaglyceroporin TbAQP2 [55], was shown to play a dominant role in uptake [56]. A low affinity
pentamidine transporter, whose physiological role remains elusive, was also shown to transport
pentamidine [54]. Loss of TbAT1 yields only low-level resistance to pentamidine, while loss of TbAQP2
yields high level resistance [56]. Pentamidine, however, is an exception among the trypanocidal
diamidines, having a highly flexible central linker chain. The shorter derivatives (e.g., diminazene,
and furamidine plus its aza-analogs), primarily use the TbAT1 aminopurine transporter for uptake [57],
and its loss gives high level resistance. Discovering a specific motif found on diamidines, aminopurines
and also melaminophenyl arsenicals, all of which can enter via the TbAT1 P2 transporter [58], led to
several efforts to create new selective trypanocides to enter via the same carrier protein [59–61].
Diamidines can enter mammalian cells and also cross the blood–brain barrier (BBB) [62].
The human facilitative organic cation transporter 1 (OCT1) is one transporter capable of
transporting pentamidine and other diamidines in mammalian cells [63,64]. ATP-dependent pumps
(e.g., the P-glycoprotein, P-gp) appear to also be able to efflux pentamidine [62], but not furamidine,
nor DB829 [65].
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3. Fexinidazole: the First Oral Treatment for HAT
In November 2018, The European Medicines Agency’s Committee for Medicinal Products for
Human Use (CHMP) offered a positive opinion on the use of oral fexinidazole for the treatment of both
stage 1 stage 1 and 2 gambiense HAT [66]. In December 2018 the DRC, the epicenter of the disease,
issued marketing authorization allowing use of the drug. Fexinidazole is given once per day for ten
days, involving a four-day loading dose of 1.8 g per day followed by six days at 1.2 g per day with
600 mg tablets. The clinical development of fexinidazole is described in an accompanying article in
this volume [67].
3.1. Pre-Clinical Development of Fexinidazole
The pathway for fexinidazole to the clinic was both long and disrupted. The drug, a 2-substituted
5-nitroimidazole, was originally synthesized as part of a program seeking anti-infectives by Hoechst
in the 1970s [68]. Frank Jennings and George Urquhart at the University of Glasgow extended
trypanocidal testing in the 1980s [69]. They could not demonstrate a full cure against the stage 2 disease
model in mice which they had developed using the T. brucei brucei GVR35 strain which develops a
slowly progressing disease in which the parasite enters the brain and establishes a CNS infection,
prior to having killed the mice in an acute infection, as most laboratory strains of T. brucei brucei do.
Administering fexinidazole as a monotherapy (given once a day for four days at 250 mg/kg), it cured
11/14 mice [69], although sequential treatment with a single dose of suramin (20 mg/kg) or diminazene
(40 mg/kg), followed by four consecutive daily doses of fexinidazole, was curative. In the case of the
suramin followed by a fexinidazole regime, a single dose of suramin, followed by four daily doses of
just 30 mg/kg fexinidazole, was curative [69]. It was later shown [70] that five days of fexinidazole
monotherapy at 200 mg/kg was curative (7/8 mice) in the stage 2 model, showing the necessity for
prolonged exposure.
The finding that many nitroheterocycles were genotoxic and potentially carcinogenic led to a
general aversion to this class of molecule for its use as pharmaceuticals for several decades. However,
nifurtimox, another nitroheterocycle, entered the anti-trypanosomal armamentarium as a combination
partner with eflornithine [4]. The nitroheterocycle known as megazol also showed interesting
trypanocidal activity [71], whilst other nitroheterocycles such as PA-824 (now registered as pretomanid
for tuberculosis [72]) came to the fore.
Thus, interest in trypanocidal nitroheterocycles was rekindled. A series of 830 nitroimidazoles
and related compounds were tested at the Swiss Tropical and Public Health Institute against T. brucei.
Trypanosoma cruzi, Leishmania donovani, and mammalian cells in vitro. The most active and selective
molecules were evaluated in secondary in vitro assays and in the mouse models of acute or chronic
trypanosomiasis. Based on these data, fexinidazole was singled out as the most promising candidate
for further development against HAT [70,73], and a dossier of information was compiled to support
the safety and efficacy of the drug [67,74].
3.2. Fexinidazole: Mode of Action and Resistance Risk
Fexinidazole is a prodrug. Its activity depends upon two consecutive electron reductions of the
NO2 group by an NADH-specific nitroreductase (TbNTR1) [75]. Diminished NTR activity leads to
resistance to fexinidazole [76] and cross-resistance to other nitroheterocycles, including nifurtimox.
The fate of the nitro-reduced product is unknown. An orthologous nitroreductase enzyme is also
found in T. cruzi [75], where it is responsible for the activation of clinically used nitroheterocycles
(e.g., benznidazole and nifurtimox). In the case of nifurtimox, T. cruzi was shown to reduce the
compound to a highly reactive species [77]. Fexinidazole is also under consideration as a new treatment
for Chagas disease [78]. For benznidazole, in vitro activation also revealed reductive activation
and ultimately disintegration of the compound to glyoxal [79]. Another study, however, failed to
demonstrate the production of glyoxal in T. cruzi, although it revealed a plethora of metabolized
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products and adducts of these benznidazole breakdown-products [80]. This led to suggestions that,
following its activation by TcNTR1, benznidazole ultimately kills through the modification of numerous
metabolite and protein targets in T. cruzi [80]. The metabolic fate of fexinidazole, following NTR1
mediated reduction, has not been determined, and the mechanism by which it kills trypanosomes is
not known. However, a similar “cluster bomb” effect, with the activated fexinidazole product of the
nitroreduction hitting multi-targets, seems likely. NTR1 has been proposed to act physiologically as an
NADH dehydrogenase involved in reducing ubiquinone to ubiquinol [81], hence its essentiality even
in bloodstream form T. brucei that requires ubiquinone-based electron transport in its mitochondrial
alternative oxidase system [82]. In nifurtimox-treated T. brucei, loss of mitochondrial membrane
potential and other mitochondrial morphology defects were noted [83]. Other nitroheterocycles,
including fexinidazole, may also exert their effects on the mitochondrion, where the drug’s activation
occurs. Knockout of a single copy of the TbNTR1 gene (trypanosomes are diploid, hence have two
copies of the gene, one on each copy of chromosome 7), led to diminished activity of the drug, albeit
by just 1.6−1.9 fold, whilst double knockout was not possible [76]. Parasites resistant to fexinidazole
could be selected in vitro under the conditions of increasing drug pressure (up to 20-fold resistance),
and these parasites lost the 3’ flanking region of one allele of NTR, leading to a 50% reduction in the
expression of the gene. The same study selected nifurtimox-resistant parasites, which lost one copy of
the gene in developing 6-fold resistance. In both cases, resistance was significantly higher compared to
the single NTR1 KO cells, indicating that other, as yet unknown, events beyond partial NTR1 loss,
contribute to resistance. A question arises as to whether there is a risk that the current use of nifurtimox
could lead to the selection of resistance to fexinidazole and vice versa. However, although diminished
nitroreductase activity can yield cross resistance, it is not clear whether parasites, even with diminished
nitroreductase, would be viable in the field, if the enzyme were critical in the insect transmitted forms
of the parasites. Moreover, with very few cases of gambiense HAT currently reported (fewer than 1000
in 2018), the probability of selecting parasites resistant to either drug under field-settings is currently
very low.
NTR1 is a typical enzyme of prokaryote origin. Salmonella typhimurium, the bacterium used in
the Ames test, possesses nitroreductase genes as well, explaining the positive mutagenicity signal
of fexinidazole and its metabolites in the Ames test. In contrast to T. brucei, however, nitroreductase
activity is dispensable in S. typhimurium, and in a nitroreductase null mutant strain fexinidazole was no
longer mutagenic [74]. Mammals do not have NTR1 orthologs, and thus, fexinidazole and fexinidazole
sulfone were inactive in micronucleus tests with human or mouse cells [74].
4. Acoziborole: A Single Dose Oral Cure for Stage 2 HAT
As the enhanced effort to counter the surging HAT epidemic of the late twentieth century
began, the prospect of an orally available drug that was able to cure stage 2, CNS-involved disease
with a single administration seemed remote. Yet, as fexinidazole and pafuramidine were entering
their first clinical trials, a novel, promising class of antimicrobial agents appeared on the scene:
the benzoxaboroles [84]. These compounds are characterized by a core scaffold based around an
oxaborole heterocycle fused to a benzene ring. Pursued by the small Californian company Anacor
Pharmaceuticals Inc. (incorporated into Pfizer Inc. in 2016), the benzoxaboroles quickly attracted
attention due to their numerous bioactivities. Activity against trypanosomes was first reported in
2010 [85], and DNDi selected this class for further work. The US-based pharmaceutical company
Scynexis was contracted to initiate an intensive program of the structure-activity-relationship work to
seek benzoxaboroles with good activity against trypanosomes. Crucially, these benzoxaboroles were
also to demonstrate pharmacokinetic properties suitable to cure stage 2 HAT; i.e., being capable of
reaching the CNS and retaining trypanocidal activity levels for long enough to obtain cure [86].
Cyrus Bacchi, the same investigator who had brought eflornithine forward for HAT in the
1980s [87], showed that a 6-carboxamido-based series cured the T. brucei strain GVR35 murine model
of stage 2 disease. Structure-activity work eventually brought forward SCYX-7158, a gem-dimethyl
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4-fluoro-2-trimethylfluoro benzamide derivative, which cured when given orally [88]. Its modest
in vitro potency against T. brucei (IC50 around 0.6 µM) [88] was offset by good pharmacokinetic
properties, giving a 100% cure in a mouse model of the stage 2 disease following a dosing of 25 mg/kg
once a day for 7 days oral dosing [88]. Preclinical testing showed no overt toxicity in mice or dogs
with a concentration of no observed adverse event limit (NOAEL) of 15 mg/kg. No binding to key
proteins (CYP450), serine/cysteine peptidase or hERG channels emerged [89]. SCYX-7158 was also
non-mutagenic in the Ames tests or standard mammalian cell genotoxicity assays [89]. Hence, phase
I clinical safety trials were approved, and in 2012, SCYX-7158, or acoziborole, became the first new
chemical entity resulting from DNDi’s program to enter clinical trials for HAT.
A phase I study that included 128 healthy male subjects of sub-Saharan African origin was
conducted in 2015 in France to assess safety, tolerability, pharmacokinetics and pharmacodynamics
after single oral, ascending doses [90]. Some adverse effects were noted, including headaches, dizziness
and GI tract reactions, as abdominal pain, nausea, vomiting, constipation and diarrhea. However,
more serious issues were not identified. This trial led to the selection of a 960 mg dose, given as a
single administration in three tablets (each with 320 mg of the active compound). Acoziborole’s long
half-life (17 days), associated with high protein binding (97.8%) also necessitated safety monitoring in
the volunteers for 210 days. Outputs from the phase I trials were good enough to enable progression
to phase II/III trials in patients in Africa, which started late in 2016 [91]. The recruitment and
dosing of patients is now complete, and follow-up is underway. Final results are eagerly awaited,
but early indications (unpublished) suggest that the drug has demonstrated remarkable efficacy and
safety profiles.
Acoziborole: Mode of Action and Resistance Risk
The mode of action and resistance mechanisms to benzoxaboroles are emerging. Acoziborole
resistance was associated with multiple genetic changes in trypanosomes [92], although it was not
possible to assign a specific gene to resistance in that study. However, among the changes in resistant
lines was an amplification in the gene copy number of the RNA cleavage and polyadenylation specificity
factor subunit 3 (CPSF3) [93]. Subsequently, CPSF3 was identified as a target for benzoxaboroles in
apicomplexan parasites Plasmodium [93] and Toxoplasma [94]. Based on this observation, and the fact
that metabolomics experiments had revealed a profound change in the methionine metabolism [95]
that might have been related to RNA processing defects, particularly given the multi-methylation of
the spliced leader sequence used in trans-splicing in trypanosomes, the effect of over-expression of
CPSF3 on sensitivity to the related benzoxaborole, AN7973, was tested [96].
Over-expression of the gene yielded a notable loss of activity [96]. Elegant experiments using
a gene over-expression library, followed by a selection of clones over-expressing genes yielding
reduced sensitivity to acoziborole itself, also identified CPSF3 [97], and over-expression confirmed
loss of sensitivity, pointing to CPSF3 as a target, if not the exclusive target, of these compounds
in trypanosomes.
Another trypanocidal benzoxaborole (of the amino-methyl subclass) was shown to be subject to a
two-step metabolic processing, involving a primary conversion using amine oxidase in host serum to an
aldehyde that is further metabolized to a carboxylate via parasite aldehyde dehydrogenase [98]. Another
valinate–amide derivative series shows considerable promise for animal African trypanosomiasis
too [99].
5. Conclusions
The twentieth century ended with human African trypanosomiasis epidemics raging across
Africa. A disease that had been brought under control in the 1960s was wreaking havoc. This led to a
concerted effort across a range of international organizations, including the WHO and newly formed
agencies including DNDi and the CPDD. The arrival of the Bill and Melinda Gates Foundation and a
re-alignment of many international aid efforts provided key investment to allow the development of
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new routes to combat HAT. The development of new drugs was central to the process. CPDD produced
an orally available cure for stage 1 HAT that ultimately failed. In the meantime, DNDi brought forward
an old nitroheterocycle, fexinidazole, and through the combined forces of persistence and diligence
worked their way around numerous perceptual hurdles related to the nitroheterocycle class, so as to
bring to the clinic the first wholly oral treatment for stage 1 and 2 HAT. As those trials were proceeding,
DNDi created a consortium to bring forward a class of compounds, the benzoxaboroles, from Anacor
Pharmaceuticals Inc., through to Scynexis and an extended collaborative team. Encouraging clinical
results for the leading candidate compound, acoziborole, now promise to deliver a drug that may cure
stage 2 HAT with a single oral dose. The ability of non-profit Product Development Partnerships to
bring new medicines to market is now proven. The turnaround in the epidemiology of HAT in the
twenty first century is a truly remarkable story and a classic model of how to create medical success.
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